India's Jubilant signs licensing deal for Gilead's COVID-19 drug

(Reuters) - India's Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc's experimental COVID-19 treatment remdesivir in 127 countries, including India.The drug earlier this month received the U.S. Food and Drug Administration's emergency use authorization to treat COVID-19 patients.Jubilant also gets the rights to manufacture the drug and scale up production in nearly all low-income and middle-income countries, as well as..